Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs ETBX 021 (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors NantBioScience
- 19 Dec 2016 Status changed from not yet recruiting to recruiting.
- 03 Oct 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016.
- 28 Apr 2016 New trial record